Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 8, Issue 359, Pages 359ra129-359ra129
Publisher
American Association for the Advancement of Science (AAAS)
Online
2016-10-06
DOI
10.1126/scitranslmed.aaf3735
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
- (2016) K. H. Metzeler et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms
- (2016) Chun Hang Au et al. Diagnostic Pathology
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome
- (2016) C Y Cher et al. Blood Cancer Journal
- Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse
- (2015) M. Garg et al. BLOOD
- Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia
- (2015) H. Gill et al. HAEMATOLOGICA
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia
- (2015) Michael R. Grunwald et al. SEMINARS IN HEMATOLOGY
- Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
- (2015) Biswanath Majumder et al. Nature Communications
- Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia
- (2015) H. Gill et al. HAEMATOLOGICA
- Homoharringtonine and omacetaxine for myeloid hematological malignancies
- (2014) Shuqing Lü et al. Journal of Hematology & Oncology
- Identification of small molecules that support human leukemia stem cell activity ex vivo
- (2014) Caroline Pabst et al. NATURE METHODS
- A Niche-Like Culture System Allowing the Maintenance of Primary Human Acute Myeloid Leukemia-Initiating Cells: A New Tool to Decipher Their Chemoresistance and Self-Renewal Mechanisms
- (2014) Emmanuel Griessinger et al. Stem Cells Translational Medicine
- An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules
- (2013) Amrita Basu et al. CELL
- Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia
- (2013) Courtney D DiNardo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial
- (2013) Jie Jin et al. LANCET ONCOLOGY
- U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia
- (2013) F. Alvandi et al. ONCOLOGIST
- Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
- (2013) T. Pemovska et al. Cancer Discovery
- FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
- (2013) M. Levis Hematology-American Society of Hematology Education Program
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
- (2012) John Nemunaitis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening
- (2012) J. W. Tyner et al. CANCER RESEARCH
- FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia
- (2012) A Y H Leung et al. LEUKEMIA
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin
- (2011) J. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started